HongyuanPharma: Actively promoting "third-generation" lithium hexafluorophosphate independent technology

Hongyuan Pharma, as an innovative enterprise, invests nearly 70 million yuan in research and development each year. It collaborates deeply with universities such as Fudan University and Wuhan University, and has established platforms like the provincial enterprise technology center and the Hubei Province Fluorochemical Engineering Technology Research Center, forming a complete innovation system. Currently, it holds 65 patents, and its innovative processes have won provincial science and technology progress awards multiple times. In the pharmaceutical field, Hongyuan Pharma has built a complete industrial chain, covering the entire route from raw materials to formulations for nitroimidazole antibacterial drugs, becoming a major global supplier of related drugs with leading market share for core products. In the new energy sector, the "rheological reverse reaction method for preparing lithium hexafluorophosphate technology" developed in collaboration with Wuhan University has reached international advanced levels and has made Hongyuan Pharma a supplier for BYD. The company is advancing its "third-generation" lithium hexafluorophosphate independent technology and is scaling up the construction of a 6,000-ton high-purity crystal project, which will enhance its market share in electrolytes after production begins